{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:39Z","timestamp":1786725759393,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Left ventricular ejection fraction (LVEF) is widely used to assess cardiac function but primarily reflects volumetric changes rather than intrinsic myocardial mechanics. Sacubitril\/Valsartan, an angiotensin receptor\u2013neprilysin inhibitor, has demonstrated significant benefits in heart failure with reduced ejection fraction (HFrEF). However, its effect on LVEF and left ventricular (LV) torsional dynamics remains insufficiently explored.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n This prospective study enrolled 100 patients with HFrEF. Baseline evaluation included clinical history, physical examination, and laboratory parameters (body mass index, blood pressure, renal function, lipid profile, and electrolytes). Echocardiographic assessment \u2013 conventional and speckle-tracking \u2013 was performed at baseline, 3 months, and 6 months to measure LVEF, LV rotation, and torsion.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Participants had a mean age of 51.5 years, and 30% had diabetes. At baseline, the median LVEF was 35.5%, which improved to 40.6% at 6 months (interquartile range (IQR) =5.1;\n P<\/jats:italic>\n < 0.01), indicating significant reverse remodeling. The LV end-diastolic index decreased from 57.5 to 52.1 (IQR = 5.4;\n P<\/jats:italic>\n < 0.01), and the end-systolic index (LVESi) decreased from 39.0 to 34.4 (IQR = 4.6;\n P<\/jats:italic>\n < 0.01). LV mass showed an IQR of 27 (246.9\u2013273.9). N-terminal pro B-type natriuretic peptide levels demonstrated a marked reduction, with an IQR of 1442.4 (1030.6\u20132473). These findings collectively reflect significant structural and functional improvement over the 6-month follow-up.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Sacubitril\/Valsartan therapy improves LVEF and LV structural dynamics in HFrEF patients, supporting its role as a superior alternative to enalapril. These findings align with evidence of approximately 20% relative risk reduction in sudden cardiac death and heart failure-related mortality among patients with an ejection fraction <40% and elevated natriuretic peptides.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jcecho.jcecho_159_25","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:04:06Z","timestamp":1778144646000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Study on Effects of Sacubitril-Valsartan on Left Ventricular Ejection Fraction, Myocardial Biomarker, and Myocardial Remodeling in Patients with Heart Failure with Reduced Ejection Fraction"],"prefix":"10.4103","volume":"36","author":[{"given":"Rishabh","family":"Gaba","sequence":"first","affiliation":[{"name":"Department of General Medicine, Central Hospital North Western Railway, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Central Hospital North Western Railway, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Kumar","family":"Meena","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Central Hospital North Western Railway, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Pabri","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Central Hospital North Western Railway, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Intas Pharmaceuticals, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"R1-20260720","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10741-015-9521-8","article-title":"Echocardiographic assessment of left ventricular systolic function: From ejection fraction to torsion","volume":"21","author":"Cameli","year":"2016","journal-title":"Heart Fail Rev"},{"key":"R2-20260720","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.4103\/0971-9784.192617","article-title":"Left ventricular global systolic function assessment by echocardiography","volume":"19","author":"Chengode","year":"2016","journal-title":"Ann Card Anaesth"},{"key":"R3-20260720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/jcecho.jcecho_118_20","article-title":"Effects of Sacubitril\/Valsartan treatment on left ventricular myocardial torsion mechanics in patients with heart failure reduced ejection fraction 2D speckle tracking echocardiography","volume":"31","author":"Elshafey","year":"2021","journal-title":"J Cardiovasc Echogr"},{"key":"R4-20260720","first-page":"125","article-title":"Sacubitril\/Valsartan improves left ventricular ejection fraction and reverses cardiac remodeling in Taiwanese patients with heart failure and reduced ejection fraction","volume":"36","author":"Liu","year":"2020","journal-title":"Acta Cardiol Sin"},{"key":"R5-20260720","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"R6-20260720","doi-asserted-by":"crossref","first-page":"953886","DOI":"10.3389\/fpubh.2022.953886","article-title":"Prevalence of multimorbidity combinations and their association with medical costs and poor health: A population-based study of U. S. adults","volume":"10","author":"Schiltz","year":"2022","journal-title":"Front Public Health"},{"key":"R7-20260720","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/eurjhf\/hfq071","article-title":"Persistence of the prognostic importance of left ventricular systolic function and heart failure after myocardial infarction: 17-year follow-up of the TRACE register","volume":"12","author":"K\u00fcmler","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R8-20260720","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCIMAGING.113.000982","article-title":"Association between left ventricular global longitudinal strain and adverse left ventricular dilatation after ST-segment-elevation myocardial infarction","volume":"7","author":"Joyce","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"R9-20260720","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"R10-20260720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4070\/kcj.2018.0373","article-title":"KSHF guidelines for the management of acute heart failure: Part I. Definition, epidemiology and diagnosis of acute heart failure","volume":"49","author":"Lee","year":"2019","journal-title":"Korean Circ J"},{"key":"R11-20260720","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF\/AHA guideline for the management of heart failure:A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R12-20260720","first-page":"100821","article-title":"Effects and clinical implications of Sacubitril\/Valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up","volume":"35","author":"Paolini","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R13-20260720","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/FJC.0000000000001202","article-title":"Add-on therapy with Sacubitril\/Valsartan and clinical outcomes in CRT-D nonresponder patients","volume":"79","author":"Russo","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"R14-20260720","doi-asserted-by":"crossref","first-page":"733475","DOI":"10.3389\/fphar.2021.733475","article-title":"Impact of Sacubitril\/Valsartan on clinical and echocardiographic parameters in heart failure patients with reduced ejection fraction: Data from a real life 2-year follow-up study","volume":"12","author":"Armentaro","year":"2021","journal-title":"Front Pharmacol"},{"key":"R15-20260720","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.amjcard.2018.12.046","article-title":"Serial measurements of left ventricular systolic and diastolic function by cardiac magnetic resonance imaging in patients with early stage breast cancer on trastuzumab","volume":"123","author":"Song","year":"2019","journal-title":"Am J Cardiol"},{"key":"R17-20260720","first-page":"100418","article-title":"Impact of Sacubitril\/Valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation","volume":"25","author":"Bayard","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R18-20260720","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/ejhf.2005","article-title":"Prospective study of biomarkers, symptom improvement and ventricular remodeling during entresto therapy for heart failure (PROVE-HF) study investigators. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"22","author":"Ibrahim","year":"2020","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of Cardiovascular Echography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcecho.jcecho_159_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:16Z","timestamp":1786724716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcecho.jcecho_159_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcecho.jcecho_159_25","relation":{},"ISSN":["2211-4122","2347-193X"],"issn-type":[{"value":"2211-4122","type":"print"},{"value":"2347-193X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}